Are non-invasive tests accurate enough to predict hepatic fibrosis in non-alcoholic fatty liver disease (NAFLD)?

Gut

Volumn 57, Issue 10, 2008, Pages 1351-1353

  Chavez Tapia, Norberto C ^a,d   Tiribelli, Claudio ^a,b,c  

^a Liver Research Center   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c Centro Studi Fegato   (Italy)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASE; DIAGNOSTIC ACCURACY; DISEASE COURSE; HUMAN; LIVER FIBROSIS; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NOTE; PRIORITY JOURNAL; VIRUS INFECTION;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BODY MASS INDEX; DIABETES MELLITUS; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; PREDICTIVE VALUE OF TESTS;

EID: 52649175966     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2008.154435     Document Type: Note

References (19)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS medicine 2006;3:e442.
2. Hanley AJ, Williams K, Gonzalez C, et al. Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study. Diabetes 2003;52:463-9.
3. Byron D, Minuk GY. Clinical hepatology: profile of an urban, hospital-based practice. Hepatology (Baltimore) 1996;24:813-5.
4. Ludwig J, Viggiano TR, McGill DB, et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-8.
5. Bedogni G, Miglioli L, Masutti F, et al. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology (Baltimore) 2005;42:44-52.
6. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Internal Med 2000;132:112-7.
7. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology (Baltimore) 1990;12:1106-10.
8. Day CP. Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005;129:375-8.
9. Ratziu V, Bugianesi E, Dixon J, et al. Histological progression of non-alcoholic fatty liver disease: a critical reassessment based on liver sampling variability. Aliment Pharmacol Therapeut 2007;26:821-30.
10. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21.
11. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology (Baltimore) 2006;44:865-73.
12. Qureshi K, Clements RH, Abrams GA. The Utility of the "NAFLD Fibrosis Score" in Morbidly Obese Subjects with NAFLD. Obesity surgery 2008;18:264-70.
13. Liu CY, McKenzie CA, Yu H, et al. Fat quantification with IDEAL gradient echo imaging: correction of bias from T(1) and noise. Magn Reson Med 2007;58:354-64.
14. Harrison SA, Oliver D, Arnold HL, et al. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008;57:1441-7.
15. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterology 2007;7:40.
16. 13C-caffeine breath test detects significant fibrosis in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2008;42:408-12.
17. Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008;40:371-8.
18. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology (Baltimore) 2008;47:455-60.
19. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (Baltimore) 2007;45:846-54.